ANOTHER BIG DAY; LEGAL WIN BOOSTS AMGEN STOCK.Byline: Phil Galewitz Associated Press Associated Press: see news agency. Associated Press (AP) Cooperative news agency, the oldest and largest in the U.S. and long the largest in the world. Amgen's scientists made it the nation's biggest biotechnology company. Its lawyers have helped keep it there. The company's shares zoomed 14 percent Monday after Amgen won the latest of a series of legal fights to protect the franchise of its blockbuster anemia drug, EPO EPO see erythropoietin. EPO Erythropoietin, see there , which sells under the commercial name Epogen. (As the Daily News reported Saturday, an arbitrator arbitrator n. one who conducts an arbitration, and serves as a judge who conducts a "mini-trial," somewhat less formally than a court trial. In most cases the arbitraror is an attorney, either alone or as part of a panel. Friday rejected Johnson & Johnson's demand that it be allowed continued marketing rights to the next generation of the drug, NESP NESP Neuroendocrine Secretory Protein NESP Navy EHF SATCOM Program NESP Nurse Educator Scholarship Program NESP Navy EHF Satellite Program NESP National Environmental Studies Project NESP National Education Supercomputer Program .) The decision means Amgen Inc. could see a big boost in sales for a product that makes up nearly half its total sales. Amgen gained $12.1875 on the Nasdaq Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. to close at $100.3125. EPO, short for erythropoetin, was created by Amgen in the early 1980s and is now one the top selling drugs in the world. It took in more than $3 billion last year for its three manufacturers, Amgen, Johnson & Johnson and France's Roche. NESP is short for novel erythropoeisis stimulating protein. This drug, now entering the final phase of human testing, is expected to largely replace EPO because it is injected just once a week instead of EPO's three-times-a-week regimen. CAPTION(S): Chart CHART: PROFITABLE DRUG |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion